Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: The baltimore longitudinal study of aging

[1] Basta G.(2004)Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes Cardiovasc. Res 63 582-592

[2] Schmidt A.M.(1998)The advanced glycation end product N (carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes Diabetes Care 21 1997-2002

[3] de Caterina R.(2004)Elevated serum levels of N -carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema Diabetologia 47 1376-1379

[4] Berg T.J.(2005)Advanced glycation end products and the kidney Am. J. Renal Physiol 289 F645-F659

[5] Clausen J.T.(2006)The advanced glycation end product N -carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension Am. J. Kidney Dis 48 571-579

[6] Torjesen P.A.(2003)Followup report on the diagnosis of diabetes mellitus Diabetes Care 26 3160-3136

[7] Dahl-Jørgensen K.(2001)Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2486-2497

[8] Bangstad H.J.(1972)Estimation of the concentration of lowdensity-lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin. Chem 18 499-502

[9] Hanssen K.F.(2004)Advanced glycoxidation end products in commonly consumed foods J. Am. Diet. Assoc 104 1287-1291

[10] Boehm B.O.(2004)Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes Endocrine J 51 537-544

[1] Basta G.(2004)Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes Cardiovasc. Res 63 582-592

[2] Schmidt A.M.(1998)The advanced glycation end product N (carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes Diabetes Care 21 1997-2002

[3] de Caterina R.(2004)Elevated serum levels of N -carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema Diabetologia 47 1376-1379

[4] Berg T.J.(2005)Advanced glycation end products and the kidney Am. J. Renal Physiol 289 F645-F659

[5] Clausen J.T.(2006)The advanced glycation end product N -carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension Am. J. Kidney Dis 48 571-579

[6] Torjesen P.A.(2003)Followup report on the diagnosis of diabetes mellitus Diabetes Care 26 3160-3136

[7] Dahl-Jørgensen K.(2001)Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2486-2497

[8] Bangstad H.J.(1972)Estimation of the concentration of lowdensity-lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin. Chem 18 499-502

[9] Hanssen K.F.(2004)Advanced glycoxidation end products in commonly consumed foods J. Am. Diet. Assoc 104 1287-1291

[10] Boehm B.O.(2004)Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes Endocrine J 51 537-544